Chimeric antigen receptor (CAR) T-cell therapy is a successful novel cell-based therapy in hemato-oncology, and it might also be a promising therapeutic option for TP53-mutant AML/MDS. This evidence concerns the gene TP53 and acute myeloid leukemia.